KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Accounts Payables: 2020-2025

Historic Accounts Payables for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Sep 2025 value amounting to $13.9 million.

  • Recursion Pharmaceuticals' Accounts Payables rose 516.59% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year increase of 516.59%. This contributed to the annual value of $21.6 million for FY2024, which is 446.75% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Accounts Payables is $13.9 million, which was down 27.85% from $19.3 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Accounts Payables' 5-year high stood at $25.1 million during Q1 2025, with a 5-year trough of $2.1 million in Q2 2023.
  • Over the past 3 years, Recursion Pharmaceuticals' median Accounts Payables value was $4.3 million (recorded in 2023), while the average stood at $9.6 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Accounts Payables crashed by 47.01% in 2024 and then skyrocketed by 516.59% in 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Accounts Payables (Quarterly) stood at $2.8 million in 2021, then soared by 62.68% to $4.6 million in 2022, then fell by 13.80% to $4.0 million in 2023, then surged by 446.75% to $21.6 million in 2024, then soared by 516.59% to $13.9 million in 2025.
  • Its Accounts Payables was $13.9 million in Q3 2025, compared to $19.3 million in Q2 2025 and $25.1 million in Q1 2025.